Literature DB >> 21640467

Essential thrombocythemia and pregnancy.

Marie-Cécile Valera1, Olivier Parant, Christophe Vayssiere, Jean-François Arnal, Bernard Payrastre.   

Abstract

Essential thrombocythaemia (ET) is an acquired myeloproliferative neoplasm, characterised by persistent thrombocytosis and a tendency for either thrombosis or haemorrhage. Among myeloproliferative neoplasms, ET is the most prevalent in young women, which constitute a special group due to their childbearing potential. An increased risk of fetal and maternal complications has been demonstrated in patients with ET. The most common pregnancy-related complication is spontaneous abortion during the first trimester. Recurrent abortion, fetal growth restriction, stillbirth and placental abruption are less frequent. Maternal complications are relatively rare and essentially represented by thromboembolic and bleeding events. Here we summarize the literature describing pregnancy and its outcome in patients with ET and discuss some recommendations for the management of pregnancy.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21640467     DOI: 10.1016/j.ejogrb.2011.04.040

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  3 in total

Review 1.  Essential thrombocythemia treatment algorithm 2018.

Authors:  Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-01-10       Impact factor: 11.037

2.  A Successful Mother and Neonate Outcome for a Woman with Essential Thrombocytosis and FV Leiden Heterozygosity.

Authors:  Marianna Politou; Serena Valsami; Irontianta Gkorezi-Ntavela; Vasilios Telonis; Efrosyni Merkouri; Panagiotis Christopoulos
Journal:  Case Rep Obstet Gynecol       Date:  2016-03-31

3.  Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.

Authors:  Gunnar Birgegård; Carlos Besses; Martin Griesshammer; Luigi Gugliotta; Claire N Harrison; Mohamed Hamdani; Jingyang Wu; Heinrich Achenbach; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2017-10-27       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.